NYSE:PBH - New York Stock Exchange, Inc. - US74112D1019 - Common Stock - Currency: USD
Revenue of $290.3 million in Q3, up 2.7% versus prior yearDiluted EPS of $1.22 in Q3 increased approximately 15% versus prior yearReduced leverage to 2.5x...
TARRYTOWN, N.Y., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2025 third...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Prestige Consumer (NYSE:PBH) just reported results for the fourth quarter of 20...
Revenue of $283.8 Million in Q2, Ahead of OutlookDiluted EPS of $1.09 in Q2, Up 2% Versus Prior YearNet Cash Provided by Operating Activities of...
TARRYTOWN, N.Y., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its first quarter ended June 30, 2024.
TARRYTOWN, N.Y., July 02, 2024 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2025 first...
TARRYTOWN, N.Y., June 06, 2024 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced it will present at the Oppenheimer Annual...
PBH stock results show that Prestige Consumer missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2024.
Revenue of $277.0 Million in Q4 and $1,125.4 Million in Fiscal 2024Solid Consumption Trends in Q4 Offset by Near-Term Supply Chain ConstraintsAchieved...
TARRYTOWN, N.Y., April 25, 2024 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2024...
The nausea-fighting brand is highlighting the cultural impact of barf bags and ushering them into a new era with a documentary, a limited-edition...
The nausea-fighting brand is highlighting the cultural impact of barf bags and ushering them into a new era with a documentary, a limited-edition collection of upcycled bags and a custom wearable art piece made from vintage bags
Revenue of $282.7 Million in Q3, Up 2.6% Versus Prior YearDiluted EPS of $1.06 in Q3, Up 2.2% Versus Prior YearReduced Leverage Ratio to 2.9x at Quarter...
TARRYTOWN, N.Y., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Insight Pharmaceuticals, a Prestige Consumer Healthcare Inc. company (“Insight”), is voluntarily...
TARRYTOWN, N.Y., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2024 third...